Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

Crohn’s Disease is a long‑lasting condition that causes inflammation in the digestive tract, leading to abdominal pain, diarrhea, weight loss and fatigue. The study focuses on people whose disease is moderately to severely active, meaning symptoms are frequent and affect daily life. The investigational medicine being tested is called JNJ-78934804, which contains two active substances, guselkumab and golimumab. It is given as a liquid that is injected subcutaneous (under the skin) using a pre‑filled syringe. For comparison, another group receives only guselkumab in the same type of injection.

The purpose of the study is to find out whether JNJ-78934804 can bring participants to a state of clinical remission (no noticeable symptoms) and an endoscopic remission (no visible inflammation when doctors look inside the gut with a camera) by week 48. Participants will receive a series of injections over about a year and will attend regular clinic visits where doctors check health, assess symptoms and may perform simple imaging to look at the gut. Throughout the study, neither the participants nor the treating doctors know which medication is being given, helping to keep the results unbiased.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Enrollment and baseline assessment

    After joining the study, a series of initial examinations are performed to record the current condition of the disease. these may include medical history, physical examination, laboratory tests, and imaging of the intestines. the information collected serves as a reference point for later comparisons.

  2. Step 2

    Randomization to a treatment group

    The participant is assigned, by a computer system, to one of two groups without knowing which group is received. this process ensures that the assignment is unbiased. the two possible groups are the test medication JNJ-78934804 (which contains guselkumab and golimumab) or the comparator medication guselkumab alone.

  3. Step 3

    Administration of study medication

    The first dose of the assigned medication is given by subcutaneous injection (injection under the skin). the exact amount of the drug and the schedule for additional doses are defined by the study protocol and will continue for the duration of the trial, which lasts up to week 48. the test medication is supplied as a solution for injection, while the comparator is provided in a pre‑filled syringe.

  4. Step 4

    Regular follow‑up visits and safety monitoring

    Throughout the study, the participant attends scheduled visits to check for any side effects, to have blood drawn for laboratory tests, and to answer questionnaires about symptoms. these visits also provide any additional doses of the medication according to the predetermined schedule.

  5. Step 5

    Week 48 efficacy evaluation

    At the end of week 48, doctors assess two main outcomes: clinical remission (meaning the signs and symptoms of Crohn’s disease have improved to a predefined level) and endoscopic remission (meaning the lining of the intestine looks healed when examined with an endoscope). the results determine whether the test medication performed better than the comparator.

  6. Step 6

    Study completion

    After the week 48 assessment, the participant’s involvement in the trial ends. any further medical care will be managed by the participant’s regular healthcare provider.

Who can join the trial?

5 criteria

  • Be at least 18 years old when you give consent to join the study.
  • Have a diagnosis of Crohn’s disease that was confirmed at least 12 weeks ago by both an endoscopic exam (a camera looking inside the intestine) and a tissue test (histopathology report).
  • Have moderately to severely active disease, shown by a Crohn’s Disease Activity Index (CDAI) score of 220 to 450, and also either an average of 4 or more bowel movements each day or an abdominal pain rating of 2 or higher on a simple pain scale.
  • Show a screening Simple Endoscopic Score for Crohn’s Disease (SES‑CD) of 6 or higher (or 4 or higher if the disease is only in the ileum, the last part of the small intestine).
  • Have had an inadequate initial response, loss of response over time, or been unable to tolerate previously approved systemic therapies (medicines that work throughout the whole body) for Crohn’s disease.

Who cannot join the trial?

4 criteria

  • Having a diagnosis of any type of colitis that is not Crohn’s disease, such as indeterminate colitis (unclear type), microscopic colitis (inflammation seen only under a microscope), ischemic colitis (damage caused by reduced blood flow), or ulcerative colitis (UC) (a different inflammatory bowel disease).
  • Having a history of short bowel syndrome (where a large part of the intestine is missing or removed), missing more than two of the five main sections of the intestine called the ileocolonic segments, or any other health problem that could make it hard to tell whether the study drug works.
  • Previously showing a weak or no initial response, losing the benefit, or having an allergy, strong reaction (hypersensitivity), or inability to tolerate the medicines guselkumab or golimumab.
  • Being pregnant, breastfeeding, planning to become pregnant, or planning to father a child while in the study or within six months after the last dose of the study medication.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • JNJ-78934804

    is the experimental treatment being tested in this study. It is a combination of two medicines, guselkumab and golimumab, that are given as a liquid injection under the skin. The purpose of this medication in the trial is to see if the combined effect of these two drugs can improve symptoms and reduce inflammation in people with moderate to severe Crohn’s disease compared with the standard therapy.

  • Guselkumab

    is the active‑controlled comparator used in the trial. It is a single‑ingredient medicine that is also given as a liquid injection under the skin. In the study, it serves as the reference treatment to determine whether the new combination drug (JNJ‑78934804) works better, the same, or worse than an existing therapy for Crohn’s disease.

What is already known about the treatment

  • JNJ-78934804

    This investigational product is a solution for injection that is given subcutaneously. It combines two monoclonal antibodies, guselkumab and golimumab, and is being studied for moderately to severely active Crohn’s disease. The drug works by blocking two key proteins, interleukin‑23 and tumor‑necrosis‑factor‑alpha, which helps lower gut inflammation. It is classified as a combination biologic therapy targeting the immune system.

  • Guselkumab

    Guselkumab is supplied as a solution for injection in a pre‑filled syringe for subcutaneous use. It is an approved medicine for conditions such as plaque psoriasis and ulcerative colitis and is now being tested in Crohn’s disease. The antibody binds to interleukin‑23, preventing this molecule from triggering inflammatory pathways. It belongs to the class of IL‑23 inhibitor monoclonal antibodies.

  • Golimumab

    Golimumab is provided as a solution for injection and is administered subcutaneously. It is an approved treatment for rheumatoid arthritis, ulcerative colitis, and psoriatic arthritis, and is being evaluated in combination with guselkumab for Crohn’s disease. The drug attaches to tumor‑necrosis‑factor‑alpha, blocking its ability to cause inflammation. It is classified as a TNF‑alpha inhibitor monoclonal antibody.

Investigated diseases

Crohn's disease - Crohn's disease is a chronic inflammatory condition that primarily affects the digestive tract, especially the small intestine and colon. In moderately to severely active disease, inflammation causes persistent abdominal pain, diarrhea, weight loss, and fatigue. The inflammation can lead to ulcers, narrowing of the intestine, and formation of fistulas. Over time, the affected bowel can become scarred, leading to strictures that may block the passage of food. Symptoms may flare up and then improve, creating a pattern of relapsing activity.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2026-525922-39-00Protocol code78934804CRD3001Estimated enrolment461 patientsSponsorJanssen Cilag International

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.